Novartis: mixed results for heart drug Entresto
(CercleFinance.com) - Novartis said that it has obtained mixed results in a late-stage trial of its drug Entresto in patients suffering from heart failure with preserved ejection fraction (HFpEF), which narrowly missed its primary endpoint.
Entresto reduced the composite primary endpoint of total heart failure hospitalisations and cardiovascular death by 13%, the Swiss drugmaker said.
However, the reduction in the primary endpoint was not "statistically significant", the group said.
On the other hand, pre-specified subgroup analyses suggest greater effects in individuals with a left ventricular ejection fraction equal to or below the median level of 57%, Novartis said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Entresto reduced the composite primary endpoint of total heart failure hospitalisations and cardiovascular death by 13%, the Swiss drugmaker said.
However, the reduction in the primary endpoint was not "statistically significant", the group said.
On the other hand, pre-specified subgroup analyses suggest greater effects in individuals with a left ventricular ejection fraction equal to or below the median level of 57%, Novartis said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.